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Abstract
Background: Osteoporosis is a serious but treatable condition. However, appropriate therapy
utilization of the disease remains suboptimal. Thus, the objective of the study was to change
physicians' therapy administration behavior in accordance with the Osteoporosis Canada 2002
guidelines.
Methods: The Project was a two year cohort study that consisted of five Quality Circle (QC)
phases that included: 1) Training & Baseline Data Collection, 2) First Educational Intervention &
First Follow-Up Data Collection 3) First Strategy Implementation Session, 4) Final Educational
Intervention & Final Follow-up Data Collection, and 5) Final Strategy Implementation Session. A
total of 340 family physicians formed 34 QCs and participated in the study. Physicians evaluated a
total of 8376, 7354 and 3673 randomly selected patient charts at baseline, follow-up #1 and the
final follow-up, respectively. Patients were divided into three groups; the high-risk, low-risk, and
low-risk without fracture groups. The generalized estimating equations technique was utilized to
model the change over time of whether physicians
Results: The odds of appropriate therapy was 1.29 (95% CI: 1.13, 1.46), and 1.41 (95% CI: 1.20,
1.66) in the high risk group, 1.15 (95% CI: 0.97, 1.36), and 1.16 (95% CI: 0.93, 1.44) in the low risk
group, and 1.20 (95% CI: 1.01, 1.43), and 1.23 (95% CI: 0.97, 1.55) in the low risk group without
fractures at follow-up #1 and the final follow-up, respectively.
Conclusion:  QCs methodology was successful in increasing physicians' appropriate use of
osteoporosis medications in accordance with Osteoporosis Canada guidelines.
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Background
Osteoporosis, a chronic debilitating disease, is a major
clinical concern in postmenopausal women. Nearly any
bone can fracture as a result of increased bone fragility.
The most frequent sites of osteoporotic fracture take place
at the hip, spine and wrist [1-4]. The major complications
of fracture include increased mortality, reduced health
related quality of life and higher care expenditures [5-14].
While osteoporosis may be a potentially crippling condi-
tion, it can be identified early during the course of the dis-
ease and effective therapy can be administered. After a
patient has been diagnosed with osteoporosis, treatment
should be initiated, given that there are many proven and
effective modern pharmacological therapies for the pre-
vention and treatment of the disease [15]. However,
despite the consequences of osteoporosis, the manage-
ment of the disease is less than optimal. For example,
Papaioannou et al. [16] evaluated patients re-fracture rates
following hip fractures in 527 patients aged 50 years. The
frequency of preventative treatments for osteoporosis was
low given the risk of re-fracture. None of the patients were
given bisphosphonates or hormone therapy and only
18% were given calcium and vitamin D. Furthermore, in
a study that obtained data on osteoporosis drug therapy in
112 patients who were diagnosed as having minimal
trauma forearm fractures, results indicated that a total of
42 patients (38%) were receiving either hormone replace-
ment therapy or using a bisphosphonate. Moreover, a
search conducted from a claims database in 30 states by
Freedman et al. identified 1162 women, age 55 years or
older who had a distal radial fracture. Of these patients,
only 22.9% were treated with at least one of the medica-
tions approved for treatment of established osteoporosis
[17]. Finally, data from the National Ambulatory Medical
Care Survey from 1993 to 1997 were examined for evi-
dence of treatment for osteoporosis or vertebral fracture
during visits by women 60 years of age and older to family
physicians. Results indicated that appropriate drug thera-
pies including calcium and vitamin D were offered to only
36% of the diagnosed patients [18].
Given the management care gap and the consequences of
osteoporosis, it is important the physicians treat patients
with osteoporosis appropriately. To reduce this care gap,
the Quality Circle (QC) project, a multifaceted integrated
disease management process strategy was developed and
implemented (19, 20). The objective of the study was to
determine and reduce the care gap in treating patients
with osteoporosis. We hypothesize that family physicians'
use of appropriate therapy will change in accordance with
the Osteoporosis Canada guidelines as a result of their
enrollment in quality circles.
Methods
The Canadian QC Study has been described elsewhere
[19,20]. Briefly, the project was designed to collect, ana-
lyze, and distribute information on physician practices in
the diagnosis and treatment of osteoporosis so that the
deficiencies in disease management may be recognized
and beneficial actions may be developed and put into
practice through QCs, a multifaceted osteoporosis educa-
tional intervention strategy involving small group meet-
ings.
Family physicians were recruited from seven provinces
across Canada. Three groups of physicians were selected
and participated in the study. Facilitators were local fam-
ily physicians recruited to lead the study meetings and
were chosen because of their involvement in continuing
professional development. Circle members were family
physicians selected from specific geographical regions
across Canada to form the QCs. A maximum of 15 physi-
cians were enrolled in each QC. An osteoporosis specialist
was recruited for each circle. The assignment of the oste-
oporosis specialist was to guide circle members on com-
plicated clinical matters.
All participating physicians provided written informed
consent. Physicians were selected because of their inter-
ests in osteoporosis. The study was approved by Health
Research Ethics Boards across Canada. The study was
sponsored by research grants from the Ontario College of
Family Physicians and the Alliance for Better Bone Health
(Procter & Gamble Pharmaceuticals Canada Inc. and
sanofi-aventis Pharma Inc.).
Overview of Project Phases
The project consisted of five QC phases that included: 1)
Training & Baseline Data Collection, 2) First Educational
Intervention & First Follow-Up Data Collection 3) First
Strategy Implementation Session, 4) Final Educational
Intervention & Final Follow-up Data Collection, and 5)
Final Strategy Implementation Session [19]. The duration
of the study consisted of 2 one year segments.
Our educational intervention consisted of eight key com-
ponents and consisted of 1) audit and feedback, 2) inter-
active small group discussions 3) use of opinion leaders,
4) remainders, 5) multiprofessional collaboration with
osteoporosis specialists, 6) nominal financial reimburse-
ment to circle members, 7) patient medicated interven-
tions 8) and educational material [19,20].
The QC educational intervention workshop was created
by a committee consisting of members from Osteoporosis
Canada, Ontario College of Family physicians, leading
physicians and scientists, and industry partners. The 2002BMC Medical Education 2009, 9:54 http://www.biomedcentral.com/1472-6920/9/54
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Osteoporosis Canada guidelines were used as the main
evidence-based reference for the program. The workshop
was administered twice and took 90–120 minutes to com-
plete [19,20].
Osteoporosis Canada Guideline Recommendations
Appropriate therapy was defined based on the Osteoporo-
sis Canada 2002 guidelines [15]. According to the guide-
lines, patients should be given osteoporosis therapy if
they have at least one of the following criteria: osteopenia
(t-score < -1.5) and prior fragility fracture, osteopenia and
at least one other major (excluding prior fracture) or two
minor risk factors for future fracture, or osteoporosis
defined as a bone mineral density t-score of less than -2.5
regardless of risk factor status. Treatment should not be
administered if the patient has osteopenia and only one
minor or no risk factors for fracture, or has normal bone
mineral density or has not had a bone density test regard-
less of their risk factor status [15].
Patients & Therapy
Eligible patients were enrolled based on the following cri-
teria: women 55 years of age and older, were known to the
clinician, and had at least two appointments in the 24
months before enrollment. The screening methods for
choosing eligible patients were carried out by the clinic
nurse to circumvent the potential of physician bias.
Patient screening was designated for one day each week
and was repeated for 8 weeks. At the end of each recruit-
ment day, the clinic nurse used the day's visit schedule to
randomly select the medical charts of three or four
patients that met the eligibility criteria of the study. A total
of 25 different patient charts were chosen for evaluation.
After making the selection, the clinic nurse inserted the
patient questionnaire into each patient chart and the phy-
sician completed the form to ascertain how they treated
osteoporosis. Based on the questionnaire responses, phy-
sician profiles were generated that showed how individual
physicians treated patients in their own practices. The pro-
files permitted anonymous comparisons of individual cir-
cle member data with their peers in their circle and with
all the participating physicians in the project. The physi-
cians' profiles were than compared to the Osteoporosis
Canada guidelines.
For the current analysis, patients were divided into three
groups. The high risk group was defined as patients with
osteoporosis based on a bone mineral density t-score of
less than -2.5 regardless of risk factor status, or osteopenia
and prior fragility fracture, osteopenia and at least one
other major risk factor (excluding prior fracture), or two
minor risk factors for future fracture (high risk group def-
inition base on Osteoporosis Canada guidelines). The low
risk group was defined as patients with osteopenia and no
prior fracture, osteopenia and at most one minor risk fac-
tor for fracture, or normal or no bone mineral density
measurements regardless of risk factor status (low risk
group definition base on Osteoporosis Canada guide-
lines). Thus, individuals at low risk may have experienced
a fracture and still be considered low risk if the patient had
normal bone density or did not have a bone density scan.
The low risk no fracture group was defined as patients
with osteopenia and no prior fracture, osteopenia and at
most one minor risk factor for fracture, or normal or no
bone mineral density measurements regardless of risk fac-
tor status (excluding patients with fracture).
The treatments that were evaluated in the current study
included alendronate, calcitonin, etidronate, hormone
replacement therapy, parathyroid hormone (PTH),
raloxifene, or risedronate. To avoid the use of hormone
replacement therapy for other conductions we excluded
all patients on this therapy if they had a history of signifi-
cant vasomotor symptoms.
Statistical Analysis
For our primary analysis, the generalized estimating equa-
tions [21] technique utilizing an exchangeable correlation
structure was used to model the change in the appropriate
use of osteoporosis therapies over time (baseline, 1st fol-
low-up, and final follow-up). The generalized estimating
equations method was performed to factor in the clus-
tered or correlated nature of the data given that individu-
als treated by the same family physician will be managed
similarly (clustered variable is the physician). For each
model, the patient is the unit of analysis and the family
physician is the unit of inference. Odds ratios (OR) and
corresponding 95% confidence intervals (CI) are calcu-
lated. Goodness-of-fit of each model was determined by
the technique created by Horton et al. [22].
The change in the appropriate use of osteoporosis thera-
pies over time was evaluated in the high risk group, the
low risk group and the low risk group without prior frac-
tures. For the high risk group, the administration of any of
the above listed therapies was defined as appropriate. If
treatment was not provided, it was considered inappropri-
ate. For the low risk group, no treatment was deemed
appropriate, whereas the administration of therapy was
inappropriate. Thus, the outcome was a binary variable (1
= appropriate use, 0 = inappropriate) and the primary
independent variable was time (baseline, follow-up #1,
and final follow-up). In addition, results were adjusted for
the patient's age (≤65/> 65 years), prior fracture status at
the hip, spine or wrist (yes/no), family history of fragility
fracture (yes/no), early menopause (yes/no), other major
risk factors for fracture (yes/no), and two or more minor
risk factors for fracture (yes/no).BMC Medical Education 2009, 9:54 http://www.biomedcentral.com/1472-6920/9/54
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To assess the robustness of the results produced by the
generalized estimating equations analyses (our primary
analysis), a random coefficient (mixed effects model) and
standard logistic regression analyses were conducted [23].
All statistical analyses were performed using the SAS/STAT
(version 9.1; SAS Institute Inc., Cary, North Carolina,
USA) software package running on Windows XP Profes-
sional. The criterion for statistical significance was set at α
= 0.05.
Results
A total of 340, 301 and 162 family physicians from across
Canada formed 34, 31, 27 QCs at baseline, follow-up 1
and the final follow-up, respectively. Family physicians
evaluated a total of 8376, 7354 and 3673 randomly
selected patient charts at baseline, follow-up #1 and the
final follow-up, respectively. Table 1 displays patient char-
acteristics. During the three data collections phases over
60% of patients were 65 years of age and older. In addi-
tion, 10.5 (883/8376), 12.6 (923/7354), and 11.8%
(434/3673) of patients had prior fractures; 63.2 (5292/
8371), 66.2 (4849/7328), and 75.3% (2755/3657) of
patients had a BMD test; and 30.5 (2555/8376), 32.9
(2417/7354), and 37.9% (1393/3673) of patients
received bisphosphonate therapy during baseline, follow-
up #1 and the final follow-up, respectively.
Appropriate Therapy Administration: Generalized 
Estimating Equations
Results revealed that family physicians use of appropriate
therapy increased following the educational interventions
in accordance with the Osteoporosis Canada 2002 guide-
lines. Compared with baseline, more high risk patients
were administered appropriate therapy. At the final fol-
low-up visit, approximately 41% of patients were given
appropriate therapy. In addition, compared with baseline,
fewer low risk patients were administered therapy. At the
final follow-up visit, approximately 86% of patients at
low risk without fractures were given appropriate therapy
(Table 2).
The odds of appropriate therapy significantly increased
following the educational interventions in the high risk
group and the low risk group without fractures by 20 to
41% (Table 3). No significant change was found in the
appropriate use of therapy in the low risk group following
the study (Table 3). The goodness-of-fit test for the analy-
ses varied from 0.0002 to 0.319.
Appropriate Therapy Administration: Random Coefficient 
and Logistic Regression Analyses
Results from the random coefficient reveal similar find-
ings to the generalized estimating equations analysis for
all three groups (Table 3). However, the logistic regression
analysis had a greater number of significant results. In
contrast to both the generalized estimating equations and
random coefficient analysis, where no significant results
were found, findings from the logistic regression analysis
indicated that appropriate therapy was significantly given
more often during follow-up # 1 for low risk patients and
during the final follow-up for low risk patients without
fracture.
Discussion
To guide physicians in treating the disease, Osteoporosis
Canada has developed and circulated the 2002 Clinical
Table 1: Patient characteristics at baseline, Follow-up #1 and Final Follow-up.
Patient characteristics Baseline
% (n)
Follow-up #1
% (n)
Final Follow-up
% (n)
>65 years 64.2 (5337/8317) 60.5 (4440/7341) 62.3 (2286/3670)
Prior hip fracture 1.8 (152/8366) 2.6 (187/7344) 2.4 (87/3667)
Prior wrist fracture 4.2 (353/8367) 5.3 (392/7345) 4.9 (180/3665)
Prior spine fracture 5.8 (486 (8365) 6.6 (481/7339) 7.1 (259/3663)
High risk patients 76.0 (6367/8376) 75.7 (5569/7354) 78.2 (2871/3673)
BMD tests
None 36.8 (3079/8317) 33.8 (2479/7328) 24.7 (902/3657)
Normal 17.8 (1490/8317) 17.7 (1295/7328) 19.3 (704/3657)
Osteopenia 24.2 (2028/8317) 31.1 (1272/7328) 35.9 (1313/3657)
Osteoporosis 21.2 (1774/8317) 17.4 (1272/7328) 20.2 (738/3657)
Any therapy 38.3 (3210/8376) 39.4 (2984/7354) 43.5 (1596/3673)
Risedronate 10.8 (908/8376) 13.7 (1008/7354) 19.9 (732/3673)
Alendronate 12.5 (1050/8376) 13.3 (979/7354) 13.0 (479/3673)
Etidronate 7.1 (597/8376) 5.9 (430/7354) 5.0 (182/3673)
Hormone replacement 6.3 (509/8025) 5.5 (389/7106) 4.3 (155/3605)
Raloxifene 2.1 (172/8376) 1.7 (123/7354) 1.6 (60/3673)
PTH 0.1 (6/8376) 0.0 (3/7354) 0.2 (7/3673)
Calcitonin 1.0 (83/8376) 0.6 (45/7354) 0.6 (22/3673)BMC Medical Education 2009, 9:54 http://www.biomedcentral.com/1472-6920/9/54
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Practice Guidelines for the Management of the disease
[15]. Nonetheless, even with guidelines, it has been dem-
onstrated that a care gap exist in managing patients in eve-
ryday clinical settings [16-18,24,25].
There are several potential reasons as to why osteoporosis
is under-treated. For instance, family physicians may have
a tendency to overlook the impact of osteoporosis given
that individuals with osteoporosis are no symptoms
(other than fracture), and may instead focus on other con-
ditions they consider more severe. Physicians may lack
confidence regarding the management of osteoporosis
and thus are not able to provided appropriate treatment
strategies, they may not be aware or may not understand
Table 2: The use of appropriate therapy in the High risk, Low risk and Low risk without fractures group at baseline, Follow-up #1 and 
Follow-up #2*
Baseline
% (n)
Follow-up #1
% (n)
Final follow-up
% (n)
Appropriate therapy
High risk group 34.7 (1040/2996) 40.1 (1243/3098) 41.2 (735/1784)
Low risk group 81.9 (2874/3506) 83.4 (2052/2460) 84.3 (782/928)
Low risk group without fractures 83.4 (2778/3332) 86.1 (1956/2272) 86.5 (763/882)
* The high risk group was defined as patients with osteopenia and prior fragility fracture, osteopenia and at least one other major (excluding prior 
fracture) or two minor risk factors for future fracture, or osteoporosis defined as a bone mineral density t-score of less than -2.5 regardless of risk 
factor status. The low risk group was defined as patients with osteopenia and no prior fracture, osteopenia and at most one minor risk factor for 
fracture, have normal or no bone mineral density measurements regardless of risk factor status (guidelines). The low risk no fracture group was 
defined as patients with osteopenia and no prior fracture, osteopenia and at most one minor risk factor for fracture, have normal or no bone 
mineral density measurements without a prior fracture. Appropriate therapy was defined as any treatment (including alendronate, calcitonin, 
etidronate, hormone replacement therapy, PTH, raloxifene, or risedronate) administered to high risk patients and no treatment administered to 
low risk patients.
Table 3: Appropriate therapy during the study determined by the Generalized estimating equations, Random coefficient, and Logistic 
regression analyses.*
Generalized estimating equations¶ Random coefficient analysis¶ Logistic regression analysis¶
Odds ratios
(95% CI)
Odds ratios
(95% CI)
Odds ratios
(95% CI)
High risk
Baseline 1 1 1
Follow-up #1 1.29
(1.13, 1.46)
1.33
(1.17, 1.50)
1.35
(1.20, 1.51)
Final follow-up 1.41
(1.20, 1.66)
1.48
(1.27, 1.72)
1.44
(1.27, 1.64)
Low risk
Baseline 1 1 1
Follow-up #1 1.15
(0.97, 1.36)
1.17
(0.99, 1.49)
1.18
(1.01, 1.37)
Final follow-up 1.16
(0.93, 1.44)
1.18
(0.93, 1.46)
1.16
(0.94, 1.42)
Low risk without fracture
Baseline 1 1 1
Follow-up #1 1.20
(1.01, 1.43)
1.23
(1.03, 1.46)
1.22
(1.05, 1.44)
Final follow-up 1.23
(0.97, 1.55)
1.24
(0.96, 1.59)
1.26
(1.01, 1.58)
* The high risk group was defined as patients with osteopenia and prior fragility fracture, osteopenia and at least one other major (excluding prior 
fracture) or two minor risk factors for future fracture, or osteoporosis defined as a bone mineral density t-score of less than -2.5 regardless of risk 
factor status. The low risk group was defined as patients with osteopenia and no prior fracture, osteopenia and at most one minor risk factor for 
fracture, have normal or no bone mineral density measurements regardless of risk factor status (guidelines). The low risk no fracture group was 
defined as patients with osteopenia and no prior fracture, osteopenia and at most one minor risk factor for fracture, have normal or no bone 
mineral density measurements without a prior fracture. Appropriate therapy was defined as any treatment (including alendronate, calcitonin, 
etidronate, hormone replacement therapy, PTH, raloxifene, or risedronate) administered to high risk patients and no treatment administered to 
low risk patients.
¶ results were adjusted for the patient's age (≤65/> 65 years), prior fracture status at the hip, spine or wrist (yes/no), family history of fragility 
fracture (yes/no), early menopause (yes/no), other major risk factors for fracture (yes/no), and two or more minor risk factors for fracture (yes/
no). For the low risk without fracture group, the prior fracture status variable was excluded from the adjusted results.BMC Medical Education 2009, 9:54 http://www.biomedcentral.com/1472-6920/9/54
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the Osteoporosis Canada's management guidelines for
osteoporosis that outline treatment options, or they may
be discouraged by low patient adherence to their medica-
tions possibly due to poor patient education and as a con-
sequence prescribe less often.
Given this care gap, and the availability of effective oste-
oporosis therapies, our study was designed to improve
patient care. Following the educational interventions that
included the distribution and discussion of educational
materials related to the 2002 OC guidelines, the evalua-
tion of physician profiles, an educational workshop, and
facilitators led small group discussions that identify barri-
ers to the management of osteoporosis and strategies to
improve patient care, family physicians demonstrated
greater odds of administering osteoporosis therapy appro-
priately over a two year period. The appropriate use of
therapy was observed in both high and low risk patients,
which revealed that physicians did not just prescribe more
therapy in general, but reduced their osteoporosis pre-
scriptions in low risk patients.
There were differences in the use of appropriate therapy
between the two low risk groups (appropriate therapy
increase significantly in the low risk group with no frac-
tures and remained unchanged in the low risk group).
This finding is interesting and may indicate that physi-
cians are more willing to treat patients with fractures
regardless of their bone density measurements (i.e. nor-
mal or no bone density measurement) in spite of the
guidelines recommendations.
To compare the results produced by the generalized esti-
mating equations analyses (our primary analysis), a ran-
dom coefficient (mixed effects model) and standard
logistic regression analyses were conducted. For the gener-
alized estimating equations analysis, a correction is made
for the within-physician correlations between the
repeated measurements by assuming a working correla-
tion structure. For the current study, the correlation
between individual physicians and their patients were
0.11, 0.10, and 0.09 for the high risk, the low risk, and the
low risk group without fractures, respectively. The gener-
alized estimating equations method is robust to an
assigned correlation structure; such that if a correlation
structure is misspecify the analysis will still obtain consist-
ent parameter estimates [21]. The random coefficient
analysis, deals with within-physician correlations by
allowing different coefficients to be random. The logistic
regression analysis does not take into account the correla-
tion and treats the data as independent [21,23].
Both the logistic and random coefficient analysis con-
firmed our finding with the generalized estimating equa-
tions analysis. However, conclusions drawn from the
results of these methods should be viewed in the context
of the models. The main concern with ordinary logistic
regression is that the analysis does not take into account
the within subject correlation of the physicians resulting
from repeated measures. As a consequence, while the
parameter estimates from the logistic regression analyses
are similar to the other models, the standard errors of the
estimates are generally smaller resulting in smaller confi-
dence intervals and p-values. As a consequence, logistic
analysis revealed more significant results for both the low
risk and low risk without fracture groups as compared
with the generalized estimating equations and random
coefficient analyses.
Furthermore, it is important to realize that the regression
coefficients calculated with generalized estimating equa-
tions method are population averaged. The regression
coefficients calculated with random coefficient analysis
can be seen as subject specific [21,23]. As a result, these
two model types have different targets of inference. Given
that we performed a trial concerned with changes in the
mean responses over time in the study population and we
were not interested in individual physician change over
time, the generalized estimating equations technique is a
more appropriate analysis as compared with the random
coefficient method.
There are other methods available for analyzing clustered
data including unweighted linear regression analysis or
robust standard errors [26]. In general, analyses may be
performed using individual-level data or aggregated at the
cluster level. Analyses at the aggregated level are con-
ducted using data derived from summary statistics for
each cluster.
Given the large number of methods available and the fact
that results may differ among techniques, it is important
that investigators specify the primary data analysis in
advance. However, while simulation studies show that
generalizing estimating equations have the greatest statis-
tical power among several commonly used methods for
analyzing binary clustered data, there are no guidelines
that evaluated what method is the most appropriate;
therefore, individual investigators will have to make judg-
ments as to which analysis to conduct [26,27].
This national study has several important strengths. For
example, the project selected a large number of family
physicians from across the country who examined over
19000 patients' charts from their own practices, which
will improve the generalizability of our findings. Further-
more, the patient chart audits were chosen at random and
did not depend on physicians self-reports, which may
mirror physicians' attitudes about their practice but not
reflect the true practice. Because single-component inter-BMC Medical Education 2009, 9:54 http://www.biomedcentral.com/1472-6920/9/54
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ventions have not consistently been found to transform
behavior [28-30], the QC project combined various meth-
odologies into one multifaceted intervention, which may
be more useful [31,32]. In addition, physicians' behavior
change observed in our study was long lasting, given that
the project was conducted over a two year period.
Nonetheless, our study has some limitations. All patients
examined in the project were postmenopausal women
and as a consequence, the relationship between appropri-
ate management over time may be different in premeno-
pausal women or male patients. Furthermore, given that
physician recruitment was based on the clinician's interest
in women's health and osteoporosis, these members may
have more knowledge in treating the disease prior to
enrollment. Also, because only physicians who were inter-
ested and willing to commit to the second year of the
project completed the final follow-up data collection, a
lower sample of physicians reduce the power of the study
to detect change over that time period. Moreover, a rand-
omized control trial of physicians is necessary to deter-
mine the precise mechanism that the educational
intervention had on physicians' behavior. Finally, it is
important to consider that Osteoporosis Canada practice
guidelines were developed and distributed to provide cli-
nicians with a summary of the best evidence from clinical
trials to help physicians make health care decisions
regarding osteoporosis; however, clinical judgment and
the patient's preference, will determine if therapy is initi-
ated. As such, 100% compliance to the guidelines is not
reasonable.
Conclusion
In conclusion, it is vital that physicians do not prescribe
medications to low risk patients and treat individuals who
are at high risk for developing fractures given that several
treatments have been shown to prevent fractures. The QC
technique is an effective knowledge translation approach
that increases family physicians' utilization of appropriate
therapy in accordance with the Osteoporosis Canada
2002 guidelines. As a result of appropriate care, patients'
health outcomes should improve by reducing the risk of
future fractures.
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